Abstract

Background

Better understanding differences associated with antibiotic prescribing for acute sinusitis can help inform antibiotic stewardship strategies. We characterized antibiotic prescribing patterns for acute sinusitis among commercially insured adults and explored differences by patient- and prescriber-level factors.

Methods

Outpatient encounters among adults aged 18 to 64 years diagnosed with sinusitis between 2016 and 2020 were identified by national administrative claims data. We classified antibiotic agents—first-line (amoxicillin-clavulanate or amoxicillin) and second-line (doxycycline, levofloxacin, or moxifloxacin)—and ≤7-day durations as guideline concordant based on clinical practice guidelines. Modified Poisson regression was used to examine the association between patient- and prescriber-level factors and guideline-concordant antibiotic prescribing.

Results

Among 4 689 850 sinusitis encounters, 53% resulted in a guideline-concordant agent, 30% in a guideline-discordant agent, and 17% in no antibiotic prescription. About 75% of first-line agents and 63% of second-line agents were prescribed for >7 days, exceeding the length of therapy recommended by clinical guidelines. Adults with sinusitis living in a rural area were less likely to receive a prescription with guideline-concordant antibiotic selection (adjusted risk ratio [aRR], 0.92; 95% CI, .92–.92) and duration (aRR, 0.77; 95% CI, .76–.77). When compared with encounters in an office setting, urgent care encounters were less likely to result in a prescription with a guideline-concordant duration (aRR, 0.76; 95% CI, .75–.76).

Conclusions

Opportunities still exist to optimize antibiotic agent selection and treatment duration for adults with acute sinusitis, especially in rural areas and urgent care settings. Recognizing specific patient- and prescriber-level factors associated with antibiotic prescribing can help inform antibiotic stewardship interventions.

Antibiotic use is a driver of antimicrobial resistance and can lead to adverse event–related emergency department visits and Clostridioides difficile infections [1–5]. Reducing inappropriate antibiotic prescribing for common outpatient conditions can help reduce antibiotic-associated adverse events and improve patient outcomes. Sinusitis is the most common indication for antibiotics in adults in the outpatient setting, with almost 3.7 million antibiotic courses dispensed per year in the United States [6–8]. The clinical practice guideline of the Infectious Diseases Society of America (IDSA) recommends 5 to 7 days of therapy for adult patients with an uncomplicated infection and a favorable initial response (ie, improvement or no worsening of symptoms after 3–5 days) [9]. However, in 2016, about 70% of antibiotics prescribed for adults with sinusitis were for ≥10 days, and about 36% of prescriptions were for guideline-discordant agents [8]. Additionally, due to the low prevalence of acute bacterial sinusitis, antibiotic therapy is often unnecessary, with one study estimating that per 1000 population, 27 antibiotic prescriptions for sinusitis were appropriate [6, 9–11]. In contrast to patients with viral sinusitis, patients with bacterial sinusitis have persistent symptoms without improvement for ≥10 days or severe signs or symptoms (ie, high fever and purulent nasal discharge or facial pain) for at least 3 to 4 consecutive days at the beginning of illness, or they experience worsening symptoms after initial improvement [9].

Previous studies have found that outpatient antibiotic prescribing varies by patient- and prescriber-level factors, such as older adults and patients residing in the South census region having a higher likelihood of receiving an antibiotic prescription or advanced practice clinicians being more likely to prescribe broad-spectrum antibiotics than physicians [12–14]. Studies examining acute respiratory tract infections also identified differences in inappropriate antibiotic prescribing by health care setting and prescriber specialty, such as older patients being more likely to receive antibiotics and physicians practicing in rural areas and urgent care centers more likely to prescribe them [15–17]. However, associations between patient- and prescriber-level factors with inappropriate antibiotic prescribing among adults with sinusitis have not been well described by more recent national-level data [18]. Our objective was to characterize antibiotic prescribing patterns and differences by patient- and prescriber-level factors in a national cohort of commercially insured outpatient adults with acute sinusitis to inform antibiotic stewardship strategies.

METHODS

Data Source

We used administrative claims data from the Merative MarketScan Commercial Database (2016–2020), which contains person-level, deidentified, longitudinal data on demographic characteristics, inpatient and outpatient procedures and services, and outpatient pharmacy-dispensed medications [19, 20]. This database includes data from >200 million unique individuals from all 50 US states and the District of Columbia, with >120 contributing employers, 500 hospitals, and 40 health plans [20]. This activity was reviewed by the Centers for Disease Control and Prevention (CDC) and was conducted consistent with applicable federal law and CDC policy (see, eg, 45 CFR part 46, 21 CFR part 56; 42 USC §241[d]; 5 USC §552a; 44 USC §3501 et seq).

Study Design and Population

We identified adults aged 18 to 64 years with a sinusitis diagnosis in an outpatient setting from 1 January 2016 to 31 December 2020. Sinusitis was identified by ICD-10-CM diagnosis codes (J01.00–J01.91; International Classification of Diseases, Tenth Revision, Clinical Modification). We required continuous enrollment and prescription drug coverage during the 180-day baseline period before the sinusitis diagnosis date. We considered an oral antibiotic prescription dispensed between the diagnosis date (day 0) and up to 3 days after to be associated with the encounter; encounters without an antibiotic prescription were also included. Individuals were eligible to have multiple encounters for sinusitis during the study period.

Using diagnosis codes from the ICD-10-CM, procedure codes from the ICD-10 Procedure Coding System, and codes from the Current Procedural Terminology/Healthcare Common Procedure Coding System, we aimed to include only encounters associated with incident acute sinusitis in the cohort. To capture encounters that reflected the clinical management indicated for most individuals in the general population with uncomplicated acute sinusitis, we excluded those resulting in prescriptions with unusual antibiotic treatment durations (1–2 or >14 days). We also excluded encounters of adults with a concurrent diagnosis of a condition for which antibiotics were warranted (eg, pneumonia, urinary tract infection, skin and soft tissue infection; Supplementary Table 1). To restrict the study population to adults with a lower likelihood of infection due to antimicrobial-resistant bacteria, we excluded encounters in which adults received hospice care or mechanical ventilation or had a serious underlying medical condition (eg, malignancy, autoimmune conditions, or receipt of immunosuppressants) within the previous 180 days of the sinusitis diagnosis date, as well as encounters of adults who had an inpatient or skilled nursing facility admission or prior antibiotic use (intravenous, intramuscular, oral) within the previous 30 days (Supplementary Tables 2 and 3).

Outcomes and Sinusitis-Related Antibiotic Prescription Definitions

The primary outcomes were receipt of an antibiotic prescription for acute sinusitis within 3 days of the sinusitis diagnosis date and whether that antibiotic selection was guideline concordant, as defined by the IDSA clinical practice guideline for acute bacterial rhinosinusitis [9]. First- and second-line antibiotics were categorized as guideline-concordant antibiotic selection. All other antibiotics were categorized as guideline discordant. First-line antibiotic agents included amoxicillin-clavulanate or amoxicillin. Although amoxicillin is not considered a first-line agent by the IDSA guideline, it is recommended for the initial management of acute sinusitis by other clinical practice guidelines, and recent evidence has demonstrated that amoxicillin has similar efficacy to amoxicillin-clavulanate for adults with acute sinusitis but with fewer gastrointestinal adverse events [21, 22]. Second-line antibiotics included doxycycline, levofloxacin, or moxifloxacin. The secondary outcome was guideline-concordant duration of therapy among events with a guideline-concordant antibiotic; prescriptions with a supply ≤7 days were classified as guideline-concordant duration, and those >7 days were classified as guideline-discordant duration.

Covariates

We assessed several patient- and prescriber-level factors, including patient age at the time of the encounter for sinusitis, patient sex (reported as biologic sex), rural-urban status, geographic region (Northeast, Midwest, South, and West), type of outpatient setting (office, urgent care, emergency department, outpatient hospital, and walk-in retail clinic), and prescriber specialty/type (family medicine, internal medicine, emergency medicine, pediatrics, otolaryngology, allergy/immunology, nurse practitioner, and physician associate). In-person and virtual encounters led by any prescriber specialty/type practicing at an office-based outpatient setting were categorized as office encounters. Individuals were classified as living in an urban area if the primary beneficiary resided in a metropolitan statistical area according to the US Census Bureau geographic mapping classification [20, 23]. Primary beneficiaries not residing in a metropolitan statistical area were classified as living in a rural area.

Statistical Analyses

We summarized the proportion of eligible encounters with antibiotic selection and duration that was guideline concordant (first- and second-line) and guideline discordant, as well as visits with no antibiotic prescriptions across patient- and prescriber-level factors. To examine the relationship between patient- and prescriber-level factors and guideline-concordant antibiotic prescribing by agent and duration, we used modified Poisson regression models to estimate risk ratios and 95% CIs for each outcome, adjusting for age, patient sex, rural-urban status, geographic region, and outpatient setting, as appropriate. All analyses were conducted with SAS version 9.4 (SAS Institute Inc). This study followed the STROBE guidelines (Strengthening Reporting of Observational Studies in Epidemiology) [24].

RESULTS

Cohort Characteristics

A total of 4 689 850 encounters for acute sinusitis met our inclusion criteria (Figure 1). There were 3 141 440 unique patients included, with an average of 1.5 encounters per patient during 2016 to 2020. Acute sinusitis encounters consisted of adults who were 45 to 64 years of age (49.3%) and female (65.5%) and lived in urban areas (74.4%) and the South (51.2%). Encounters often occurred in an office setting (81.1%) and were commonly linked to a family medicine physician (39.3%; Supplementary Table 4).

Derivation of sinusitis cohort from Merative MarketScan Commercial Database, United States, 2016–2020.
Figure 1.

Derivation of sinusitis cohort from Merative MarketScan Commercial Database, United States, 2016–2020.

In total, 815 543 (17.4%) sinusitis encounters did not result in an antibiotic prescription (Table 1). About 21% of encounters for adults aged 18 to 24 years, 18% for adults aged 25 to 44 years, and 16% for adults aged 45 to 64 years resulted in no antibiotic prescription. Most encounters that occurred at an emergency department did not result in an antibiotic prescription (57.3%). There were 3 874 307 (82.6%) sinusitis encounters with an antibiotic prescription; most were for amoxicillin-clavulanate (38.5%), followed by macrolides (22.0%), amoxicillin (13.4%), and doxycycline (9.0%; Table 2). Of all sinusitis encounters, 2 490 562 (53.1%) resulted in an antibiotic prescription for a guideline-concordant agent (42.9% first-line and 10.2% second-line) and 1 383 745 (29.5%) in a guideline-discordant agent. Encounters for adults residing in rural areas yielded a slightly higher proportion of prescriptions for a guideline-discordant agent as compared with encounters for those residing in urban areas (33.9% vs 28.6%). Encounters at an office setting and urgent care frequently resulted in a guideline-discordant agent (30.5% and 27.5%, respectively). Overall, the median treatment duration for adults with acute sinusitis was 10 days (IQR, 7–10), and the median durations for encounters resulting in guideline-concordant and guideline-discordant durations were 5 days (IQR, 5–7) and 10 days (IQR, 10–10), respectively. About 75% of first-line agents and 63% of second-line agents were prescribed for >7 days (Table 3). Additional patient information and prescriber-level factors by overall antibiotic prescribing, guideline-concordant agent selection, and guideline-concordant duration are shown in Supplementary Table 5.

Table 1.

Characteristics of Outpatient Encounters of Commercially Insured Adults Diagnosed With Acute Sinusitis by Clinical Management Group, Merative MarketScan Commercial Database, United States, 2016–2020

Guideline-Concordant Agent
TotalNo Antibiotic AgentFirst-lineSecond-lineGuideline-Discordant Agent
CharacteristicNo.%No.%No.%No.%No.%
All encounters4 689 850100815 54317.42 010 31642.9480 24610.21 383 74529.5
Age group, y
 18–24570 309100119 36720.9248 75643.635 7216.3166 46529.2
 25–441 808 830100329 18818.2816 10345.1165 9319.2497 60827.5
 45–642 310 711100366 98815.9945 45740.9278 59412.1719 67231.1
Sex
 Female3 073 665100525 48017.11 301 30142.3321 76310.5925 12130.1
 Male1 616 185100290 06317.9709 01543.9158 4839.8458 62428.4
Rural-urban status
 Urban3 487 402100623 52017.91 508 57743.3357 97110.3997 33428.6
 Rural628 00510099 52515.8255 42640.760 1409.6212 91433.9
 Missing/unknown574 44310092 49816.1246 31342.962 13510.8173 49730.2
Geographic region
 South2 400 182100410 48317.11 001 65541.7239 94910.0748 09531.2
 Midwest980 540100154 40015.7437 85644.7111 94611.4276 33828.2
 Northeast800 905100147 99618.5345 43143.179 72410.0227 75428.4
 West508 223100102 66420.2225 37444.348 6279.6131 55825.9
Outpatient setting
 Office3 802 503100653 29517.21 602 08342.1388 79810.21 158 32730.5
 Urgent care697 010100106 26815.3326 38046.872 69810.4191 66427.5
 Outpatient hospital42 15010013 26131.517 01340.439429.3793418.8
 Walk-in retail clinic33 486100502615.019 86959.3503615.0355510.6
 Emergency department24 48710014 04157.3601224.611654.8326913.3
 Other31 206100954630.613 56143.528729.2522716.7
 Missing/unknown59 00810014 10623.925 39843.057359.713 76923.3
Prescriber specialty/type
 Family medicine1 842 698100285 35215.5756 91141.1184 91410.0615 52133.4
 Internal medicine574 399100106 67418.6211 78636.960 07910.5195 86034.1
 Nurse practitioner412 41510064 59115.7199 51548.447 98811.6100 32124.3
 Physician associate149 05010021 40414.469 96546.917 51411.840 16726.9
 Emergency medicine143 22010027 03918.962 22443.414 31810.039 63927.7
 Pediatrician81 15310011 86514.637 68646.431383.928 46435.1
 Otolaryngology78 80610031 57440.119 20924.457587.322 26528.2
 Allergy/immunology41 58310018 84445.3863820.826206.311 48127.6
 Other703 432100141 34420.1329 41946.875 88410.8156 78522.3
 Missing/unknown663 094100106 85616.1314 96347.568 03310.3173 24226.1
Guideline-Concordant Agent
TotalNo Antibiotic AgentFirst-lineSecond-lineGuideline-Discordant Agent
CharacteristicNo.%No.%No.%No.%No.%
All encounters4 689 850100815 54317.42 010 31642.9480 24610.21 383 74529.5
Age group, y
 18–24570 309100119 36720.9248 75643.635 7216.3166 46529.2
 25–441 808 830100329 18818.2816 10345.1165 9319.2497 60827.5
 45–642 310 711100366 98815.9945 45740.9278 59412.1719 67231.1
Sex
 Female3 073 665100525 48017.11 301 30142.3321 76310.5925 12130.1
 Male1 616 185100290 06317.9709 01543.9158 4839.8458 62428.4
Rural-urban status
 Urban3 487 402100623 52017.91 508 57743.3357 97110.3997 33428.6
 Rural628 00510099 52515.8255 42640.760 1409.6212 91433.9
 Missing/unknown574 44310092 49816.1246 31342.962 13510.8173 49730.2
Geographic region
 South2 400 182100410 48317.11 001 65541.7239 94910.0748 09531.2
 Midwest980 540100154 40015.7437 85644.7111 94611.4276 33828.2
 Northeast800 905100147 99618.5345 43143.179 72410.0227 75428.4
 West508 223100102 66420.2225 37444.348 6279.6131 55825.9
Outpatient setting
 Office3 802 503100653 29517.21 602 08342.1388 79810.21 158 32730.5
 Urgent care697 010100106 26815.3326 38046.872 69810.4191 66427.5
 Outpatient hospital42 15010013 26131.517 01340.439429.3793418.8
 Walk-in retail clinic33 486100502615.019 86959.3503615.0355510.6
 Emergency department24 48710014 04157.3601224.611654.8326913.3
 Other31 206100954630.613 56143.528729.2522716.7
 Missing/unknown59 00810014 10623.925 39843.057359.713 76923.3
Prescriber specialty/type
 Family medicine1 842 698100285 35215.5756 91141.1184 91410.0615 52133.4
 Internal medicine574 399100106 67418.6211 78636.960 07910.5195 86034.1
 Nurse practitioner412 41510064 59115.7199 51548.447 98811.6100 32124.3
 Physician associate149 05010021 40414.469 96546.917 51411.840 16726.9
 Emergency medicine143 22010027 03918.962 22443.414 31810.039 63927.7
 Pediatrician81 15310011 86514.637 68646.431383.928 46435.1
 Otolaryngology78 80610031 57440.119 20924.457587.322 26528.2
 Allergy/immunology41 58310018 84445.3863820.826206.311 48127.6
 Other703 432100141 34420.1329 41946.875 88410.8156 78522.3
 Missing/unknown663 094100106 85616.1314 96347.568 03310.3173 24226.1

Some row percentages may not be equal to 100.0% due to rounding.

Table 1.

Characteristics of Outpatient Encounters of Commercially Insured Adults Diagnosed With Acute Sinusitis by Clinical Management Group, Merative MarketScan Commercial Database, United States, 2016–2020

Guideline-Concordant Agent
TotalNo Antibiotic AgentFirst-lineSecond-lineGuideline-Discordant Agent
CharacteristicNo.%No.%No.%No.%No.%
All encounters4 689 850100815 54317.42 010 31642.9480 24610.21 383 74529.5
Age group, y
 18–24570 309100119 36720.9248 75643.635 7216.3166 46529.2
 25–441 808 830100329 18818.2816 10345.1165 9319.2497 60827.5
 45–642 310 711100366 98815.9945 45740.9278 59412.1719 67231.1
Sex
 Female3 073 665100525 48017.11 301 30142.3321 76310.5925 12130.1
 Male1 616 185100290 06317.9709 01543.9158 4839.8458 62428.4
Rural-urban status
 Urban3 487 402100623 52017.91 508 57743.3357 97110.3997 33428.6
 Rural628 00510099 52515.8255 42640.760 1409.6212 91433.9
 Missing/unknown574 44310092 49816.1246 31342.962 13510.8173 49730.2
Geographic region
 South2 400 182100410 48317.11 001 65541.7239 94910.0748 09531.2
 Midwest980 540100154 40015.7437 85644.7111 94611.4276 33828.2
 Northeast800 905100147 99618.5345 43143.179 72410.0227 75428.4
 West508 223100102 66420.2225 37444.348 6279.6131 55825.9
Outpatient setting
 Office3 802 503100653 29517.21 602 08342.1388 79810.21 158 32730.5
 Urgent care697 010100106 26815.3326 38046.872 69810.4191 66427.5
 Outpatient hospital42 15010013 26131.517 01340.439429.3793418.8
 Walk-in retail clinic33 486100502615.019 86959.3503615.0355510.6
 Emergency department24 48710014 04157.3601224.611654.8326913.3
 Other31 206100954630.613 56143.528729.2522716.7
 Missing/unknown59 00810014 10623.925 39843.057359.713 76923.3
Prescriber specialty/type
 Family medicine1 842 698100285 35215.5756 91141.1184 91410.0615 52133.4
 Internal medicine574 399100106 67418.6211 78636.960 07910.5195 86034.1
 Nurse practitioner412 41510064 59115.7199 51548.447 98811.6100 32124.3
 Physician associate149 05010021 40414.469 96546.917 51411.840 16726.9
 Emergency medicine143 22010027 03918.962 22443.414 31810.039 63927.7
 Pediatrician81 15310011 86514.637 68646.431383.928 46435.1
 Otolaryngology78 80610031 57440.119 20924.457587.322 26528.2
 Allergy/immunology41 58310018 84445.3863820.826206.311 48127.6
 Other703 432100141 34420.1329 41946.875 88410.8156 78522.3
 Missing/unknown663 094100106 85616.1314 96347.568 03310.3173 24226.1
Guideline-Concordant Agent
TotalNo Antibiotic AgentFirst-lineSecond-lineGuideline-Discordant Agent
CharacteristicNo.%No.%No.%No.%No.%
All encounters4 689 850100815 54317.42 010 31642.9480 24610.21 383 74529.5
Age group, y
 18–24570 309100119 36720.9248 75643.635 7216.3166 46529.2
 25–441 808 830100329 18818.2816 10345.1165 9319.2497 60827.5
 45–642 310 711100366 98815.9945 45740.9278 59412.1719 67231.1
Sex
 Female3 073 665100525 48017.11 301 30142.3321 76310.5925 12130.1
 Male1 616 185100290 06317.9709 01543.9158 4839.8458 62428.4
Rural-urban status
 Urban3 487 402100623 52017.91 508 57743.3357 97110.3997 33428.6
 Rural628 00510099 52515.8255 42640.760 1409.6212 91433.9
 Missing/unknown574 44310092 49816.1246 31342.962 13510.8173 49730.2
Geographic region
 South2 400 182100410 48317.11 001 65541.7239 94910.0748 09531.2
 Midwest980 540100154 40015.7437 85644.7111 94611.4276 33828.2
 Northeast800 905100147 99618.5345 43143.179 72410.0227 75428.4
 West508 223100102 66420.2225 37444.348 6279.6131 55825.9
Outpatient setting
 Office3 802 503100653 29517.21 602 08342.1388 79810.21 158 32730.5
 Urgent care697 010100106 26815.3326 38046.872 69810.4191 66427.5
 Outpatient hospital42 15010013 26131.517 01340.439429.3793418.8
 Walk-in retail clinic33 486100502615.019 86959.3503615.0355510.6
 Emergency department24 48710014 04157.3601224.611654.8326913.3
 Other31 206100954630.613 56143.528729.2522716.7
 Missing/unknown59 00810014 10623.925 39843.057359.713 76923.3
Prescriber specialty/type
 Family medicine1 842 698100285 35215.5756 91141.1184 91410.0615 52133.4
 Internal medicine574 399100106 67418.6211 78636.960 07910.5195 86034.1
 Nurse practitioner412 41510064 59115.7199 51548.447 98811.6100 32124.3
 Physician associate149 05010021 40414.469 96546.917 51411.840 16726.9
 Emergency medicine143 22010027 03918.962 22443.414 31810.039 63927.7
 Pediatrician81 15310011 86514.637 68646.431383.928 46435.1
 Otolaryngology78 80610031 57440.119 20924.457587.322 26528.2
 Allergy/immunology41 58310018 84445.3863820.826206.311 48127.6
 Other703 432100141 34420.1329 41946.875 88410.8156 78522.3
 Missing/unknown663 094100106 85616.1314 96347.568 03310.3173 24226.1

Some row percentages may not be equal to 100.0% due to rounding.

Table 2.

Distribution of Antibiotics Prescribed During Outpatient Encounters of Commercially Insured Adults With Acute Sinusitis, United States, 2016–2020 (N = 3 874 307)

Total
Antibiotic AgentNo.%
First-line
 Amoxicillin-clavulanate1 492 20238.5
 Amoxicillin518 11413.4
Second-line
 Doxycycline350 4039.0
 Levofloxacin124 7553.2
 Moxifloxacin50880.1
Guideline discordant
 Azithromycin795 18220.5
 Cefdinir262 2386.8
 Clarithromycin57 0921.5
 Sulfamethoxazole-trimethoprim54 8651.4
 Cephalexin44 1941.1
 Ciprofloxacin25 4760.7
 Clindamycin18 8660.5
 Cefprozil12 3920.3
 Cefpodoxime proxetil20520.1
 Othera111 3882.9
Total
Antibiotic AgentNo.%
First-line
 Amoxicillin-clavulanate1 492 20238.5
 Amoxicillin518 11413.4
Second-line
 Doxycycline350 4039.0
 Levofloxacin124 7553.2
 Moxifloxacin50880.1
Guideline discordant
 Azithromycin795 18220.5
 Cefdinir262 2386.8
 Clarithromycin57 0921.5
 Sulfamethoxazole-trimethoprim54 8651.4
 Cephalexin44 1941.1
 Ciprofloxacin25 4760.7
 Clindamycin18 8660.5
 Cefprozil12 3920.3
 Cefpodoxime proxetil20520.1
 Othera111 3882.9

Some column percentages may not be equal to 100.0% due to rounding.

aOther includes cefaclor, cefadroxil, cefixime, ceftibuten, cefuroxime, dicloxacillin, erythromycin, fosfomycin, linezolid, metronidazole, minocycline, nitrofurantoin, ofloxacin, penicillin, rifampin, tetracycline, trimethoprim, and vancomycin.

Table 2.

Distribution of Antibiotics Prescribed During Outpatient Encounters of Commercially Insured Adults With Acute Sinusitis, United States, 2016–2020 (N = 3 874 307)

Total
Antibiotic AgentNo.%
First-line
 Amoxicillin-clavulanate1 492 20238.5
 Amoxicillin518 11413.4
Second-line
 Doxycycline350 4039.0
 Levofloxacin124 7553.2
 Moxifloxacin50880.1
Guideline discordant
 Azithromycin795 18220.5
 Cefdinir262 2386.8
 Clarithromycin57 0921.5
 Sulfamethoxazole-trimethoprim54 8651.4
 Cephalexin44 1941.1
 Ciprofloxacin25 4760.7
 Clindamycin18 8660.5
 Cefprozil12 3920.3
 Cefpodoxime proxetil20520.1
 Othera111 3882.9
Total
Antibiotic AgentNo.%
First-line
 Amoxicillin-clavulanate1 492 20238.5
 Amoxicillin518 11413.4
Second-line
 Doxycycline350 4039.0
 Levofloxacin124 7553.2
 Moxifloxacin50880.1
Guideline discordant
 Azithromycin795 18220.5
 Cefdinir262 2386.8
 Clarithromycin57 0921.5
 Sulfamethoxazole-trimethoprim54 8651.4
 Cephalexin44 1941.1
 Ciprofloxacin25 4760.7
 Clindamycin18 8660.5
 Cefprozil12 3920.3
 Cefpodoxime proxetil20520.1
 Othera111 3882.9

Some column percentages may not be equal to 100.0% due to rounding.

aOther includes cefaclor, cefadroxil, cefixime, ceftibuten, cefuroxime, dicloxacillin, erythromycin, fosfomycin, linezolid, metronidazole, minocycline, nitrofurantoin, ofloxacin, penicillin, rifampin, tetracycline, trimethoprim, and vancomycin.

Table 3.

Distribution of Antibiotics Prescribed in Outpatient Encounters of Commercially Insured Adults With Acute Sinusitis by Duration, United States, 2016–2020

Total (n = 3 874 307)3–7 d (n = 1 557 743)8–14 d (n = 2 316 564)
Antibiotic AgentNo.%No.%No.%
First-line2 010 316100507 63525.31 502 68174.7
 Amoxicillin-clavulanate1 492 202100411 74627.61 080 45672.4
 Amoxicillin518 11410095 88918.5422 22581.5
Second-line480 246100175 62136.6304 62563.4
 Doxycycline350 403100129 97537.1220 42862.9
 Fluoroquinolonesa129 84310045 64635.284 19764.8
Guideline discordant1 383 745100874 48763.2509 25836.8
 Macrolidesb852 274100791 79492.960 4807.1
 Cephalosporinsc425 17610057 59913.5367 57786.5
 Otherd106 29510025 09423.681 20176.4
Total (n = 3 874 307)3–7 d (n = 1 557 743)8–14 d (n = 2 316 564)
Antibiotic AgentNo.%No.%No.%
First-line2 010 316100507 63525.31 502 68174.7
 Amoxicillin-clavulanate1 492 202100411 74627.61 080 45672.4
 Amoxicillin518 11410095 88918.5422 22581.5
Second-line480 246100175 62136.6304 62563.4
 Doxycycline350 403100129 97537.1220 42862.9
 Fluoroquinolonesa129 84310045 64635.284 19764.8
Guideline discordant1 383 745100874 48763.2509 25836.8
 Macrolidesb852 274100791 79492.960 4807.1
 Cephalosporinsc425 17610057 59913.5367 57786.5
 Otherd106 29510025 09423.681 20176.4

aFluoroquinolones include levofloxacin and moxifloxacin.

bMacrolides include azithromycin and clarithromycin.

cCephalosporins include cefaclor, cefadroxil, cefdinir, cefixime, cefpodoxime, cefprozil, ceftibuten, cefuroxime, and cephalexin.

dOther includes ciprofloxacin, clindamycin, dicloxacillin, erythromycin, fosfomycin, linezolid, metronidazole, minocycline, nitrofurantoin, ofloxacin, penicillin, rifampin, sulfamethoxazole-trimethoprim, tetracycline, trimethoprim, and vancomycin.

Table 3.

Distribution of Antibiotics Prescribed in Outpatient Encounters of Commercially Insured Adults With Acute Sinusitis by Duration, United States, 2016–2020

Total (n = 3 874 307)3–7 d (n = 1 557 743)8–14 d (n = 2 316 564)
Antibiotic AgentNo.%No.%No.%
First-line2 010 316100507 63525.31 502 68174.7
 Amoxicillin-clavulanate1 492 202100411 74627.61 080 45672.4
 Amoxicillin518 11410095 88918.5422 22581.5
Second-line480 246100175 62136.6304 62563.4
 Doxycycline350 403100129 97537.1220 42862.9
 Fluoroquinolonesa129 84310045 64635.284 19764.8
Guideline discordant1 383 745100874 48763.2509 25836.8
 Macrolidesb852 274100791 79492.960 4807.1
 Cephalosporinsc425 17610057 59913.5367 57786.5
 Otherd106 29510025 09423.681 20176.4
Total (n = 3 874 307)3–7 d (n = 1 557 743)8–14 d (n = 2 316 564)
Antibiotic AgentNo.%No.%No.%
First-line2 010 316100507 63525.31 502 68174.7
 Amoxicillin-clavulanate1 492 202100411 74627.61 080 45672.4
 Amoxicillin518 11410095 88918.5422 22581.5
Second-line480 246100175 62136.6304 62563.4
 Doxycycline350 403100129 97537.1220 42862.9
 Fluoroquinolonesa129 84310045 64635.284 19764.8
Guideline discordant1 383 745100874 48763.2509 25836.8
 Macrolidesb852 274100791 79492.960 4807.1
 Cephalosporinsc425 17610057 59913.5367 57786.5
 Otherd106 29510025 09423.681 20176.4

aFluoroquinolones include levofloxacin and moxifloxacin.

bMacrolides include azithromycin and clarithromycin.

cCephalosporins include cefaclor, cefadroxil, cefdinir, cefixime, cefpodoxime, cefprozil, ceftibuten, cefuroxime, and cephalexin.

dOther includes ciprofloxacin, clindamycin, dicloxacillin, erythromycin, fosfomycin, linezolid, metronidazole, minocycline, nitrofurantoin, ofloxacin, penicillin, rifampin, sulfamethoxazole-trimethoprim, tetracycline, trimethoprim, and vancomycin.

Association Between Encounter Characteristics and Acute Sinusitis Management

Encounter characteristics associated with any antibiotic prescribing, guideline-concordant prescribing, and guideline-concordant durations included patient age group, patient sex, region, rural-urban status, and outpatient clinical setting (Table 4). Specifically, encounters among adults aged 25 to 44 years vs 18 to 24 years were associated with any antibiotic prescribing (adjusted risk ratio [aRR], 1.04; 95% CI, 1.04–1.04), increased prescribing for a guideline-concordant agent (aRR, 1.05; 95% CI, 1.04–1.05), and increased guideline-concordant duration (aRR, 1.21; 95% CI, 1.20–1.22). Female patients were less likely to receive a guideline-concordant agent (aRR, 0.97; 95% CI, .97–.98), but among those prescribed a guideline-concordant agent, they were more likely to receive guideline-concordant durations (aRR, 1.05; 95% CI, 1.05–1.06). Encounters among adults residing in the Southern or Northeastern regions vs the Western region were associated with increased guideline-concordant durations (South vs West: aRR, 1.03 [95% CI, 1.02–1.04]; Northeast vs West: aRR, 1.02 [95% CI, 1.01–1.02]).

Table 4.

Estimates for the Association Between Individual- and Prescriber-Level Factors by Antibiotic Prescribing Model for Acute Sinusitis Management, Merative MarketScan Commercial Database, United States, 2016–2020

Any Antibiotic AgentaGuideline-Concordant AgentbGuideline-Concordant Durationb
CharacteristicaRR95% CIaRR95% CIaRR95% CI
Age group, y
 18–241 [Reference]1 [Reference]1 [Reference]
 25–441.041.04–1.041.051.04–1.051.211.20–1.22
 45–641.071.07–1.071.001.00–1.001.101.09–1.11
Sex
 Male1 [Reference]1 [Reference]1 [Reference]
 Female1.011.01–1.010.97.97–.981.051.05–1.06
Rural-urban status
 Urban1 [Reference]1 [Reference]1 [Reference]
 Rural1.021.02–1.020.92.92–.920.77.76–.77
Geographic region
 West1 [Reference]1 [Reference]1 [Reference]
 South1.041.03–1.040.94.93–.941.031.02–1.04
 Midwest1.061.06–1.060.98.98–.990.94.93–.95
 Northeast1.021.01–1.020.98.98–.981.021.01–1.02
Outpatient setting
 Office1 [Reference]1 [Reference]1 [Reference]
 Urgent care1.031.03–1.031.021.02–1.030.76.75–.76
 Otherc0.84.83–.841.151.14–1.151.301.28–1.31
Any Antibiotic AgentaGuideline-Concordant AgentbGuideline-Concordant Durationb
CharacteristicaRR95% CIaRR95% CIaRR95% CI
Age group, y
 18–241 [Reference]1 [Reference]1 [Reference]
 25–441.041.04–1.041.051.04–1.051.211.20–1.22
 45–641.071.07–1.071.001.00–1.001.101.09–1.11
Sex
 Male1 [Reference]1 [Reference]1 [Reference]
 Female1.011.01–1.010.97.97–.981.051.05–1.06
Rural-urban status
 Urban1 [Reference]1 [Reference]1 [Reference]
 Rural1.021.02–1.020.92.92–.920.77.76–.77
Geographic region
 West1 [Reference]1 [Reference]1 [Reference]
 South1.041.03–1.040.94.93–.941.031.02–1.04
 Midwest1.061.06–1.060.98.98–.990.94.93–.95
 Northeast1.021.01–1.020.98.98–.981.021.01–1.02
Outpatient setting
 Office1 [Reference]1 [Reference]1 [Reference]
 Urgent care1.031.03–1.031.021.02–1.030.76.75–.76
 Otherc0.84.83–.841.151.14–1.151.301.28–1.31

Data are adjusted by age group, sex, rural-urban status, geographic region, and outpatient setting. Visits with missing rural-urban status and setting type are excluded. Total sample sizes for models differ from the totals in Table 1 because of these restrictions. Final model sample sizes are as follows: 3 348 915/4 059 509 (82.5%) for any antibiotic, 2 152 562/3 349 915 (64.3%) for guideline-concordant agent, and 587 842/2 152 562 (27.3%) for guideline-concordant duration.

Abbreviations: aRR, adjusted risk ratio; CI, confidence interval.

aFirst-line, second-line, and guideline-discordant agents.

bFirst- and second-line agents.

cEmergency department, outpatient hospital, walk-in retail clinic, and other outpatient settings.

Table 4.

Estimates for the Association Between Individual- and Prescriber-Level Factors by Antibiotic Prescribing Model for Acute Sinusitis Management, Merative MarketScan Commercial Database, United States, 2016–2020

Any Antibiotic AgentaGuideline-Concordant AgentbGuideline-Concordant Durationb
CharacteristicaRR95% CIaRR95% CIaRR95% CI
Age group, y
 18–241 [Reference]1 [Reference]1 [Reference]
 25–441.041.04–1.041.051.04–1.051.211.20–1.22
 45–641.071.07–1.071.001.00–1.001.101.09–1.11
Sex
 Male1 [Reference]1 [Reference]1 [Reference]
 Female1.011.01–1.010.97.97–.981.051.05–1.06
Rural-urban status
 Urban1 [Reference]1 [Reference]1 [Reference]
 Rural1.021.02–1.020.92.92–.920.77.76–.77
Geographic region
 West1 [Reference]1 [Reference]1 [Reference]
 South1.041.03–1.040.94.93–.941.031.02–1.04
 Midwest1.061.06–1.060.98.98–.990.94.93–.95
 Northeast1.021.01–1.020.98.98–.981.021.01–1.02
Outpatient setting
 Office1 [Reference]1 [Reference]1 [Reference]
 Urgent care1.031.03–1.031.021.02–1.030.76.75–.76
 Otherc0.84.83–.841.151.14–1.151.301.28–1.31
Any Antibiotic AgentaGuideline-Concordant AgentbGuideline-Concordant Durationb
CharacteristicaRR95% CIaRR95% CIaRR95% CI
Age group, y
 18–241 [Reference]1 [Reference]1 [Reference]
 25–441.041.04–1.041.051.04–1.051.211.20–1.22
 45–641.071.07–1.071.001.00–1.001.101.09–1.11
Sex
 Male1 [Reference]1 [Reference]1 [Reference]
 Female1.011.01–1.010.97.97–.981.051.05–1.06
Rural-urban status
 Urban1 [Reference]1 [Reference]1 [Reference]
 Rural1.021.02–1.020.92.92–.920.77.76–.77
Geographic region
 West1 [Reference]1 [Reference]1 [Reference]
 South1.041.03–1.040.94.93–.941.031.02–1.04
 Midwest1.061.06–1.060.98.98–.990.94.93–.95
 Northeast1.021.01–1.020.98.98–.981.021.01–1.02
Outpatient setting
 Office1 [Reference]1 [Reference]1 [Reference]
 Urgent care1.031.03–1.031.021.02–1.030.76.75–.76
 Otherc0.84.83–.841.151.14–1.151.301.28–1.31

Data are adjusted by age group, sex, rural-urban status, geographic region, and outpatient setting. Visits with missing rural-urban status and setting type are excluded. Total sample sizes for models differ from the totals in Table 1 because of these restrictions. Final model sample sizes are as follows: 3 348 915/4 059 509 (82.5%) for any antibiotic, 2 152 562/3 349 915 (64.3%) for guideline-concordant agent, and 587 842/2 152 562 (27.3%) for guideline-concordant duration.

Abbreviations: aRR, adjusted risk ratio; CI, confidence interval.

aFirst-line, second-line, and guideline-discordant agents.

bFirst- and second-line agents.

cEmergency department, outpatient hospital, walk-in retail clinic, and other outpatient settings.

Encounters among adults living in rural areas vs urban areas were 8% less likely to receive a guideline-concordant agent (aRR, 0.92; 95% CI, .92–.92) and 23% less likely to receive a prescription with a guideline-concordant duration (aRR, 0.77; 95% CI, .76–.77). Finally, encounters at an urgent care vs office setting were associated with any antibiotic prescribing (aRR, 1.03; 95% CI, 1.03–1.03) and guideline-concordant prescribing (aRR, 1.02; 95% CI, 1.02–1.03) and were 24% less likely to receive a guideline-concordant duration (aRR, 0.76; 95% CI, .75–.76).

DISCUSSION

In this nationwide cohort study of commercially insured adults diagnosed with acute sinusitis in the outpatient setting, most encounters resulted in an antibiotic prescription, with nearly one-third of encounters resulting in a guideline-discordant agent. Additionally, about 75% of encounters with a guideline-concordant agent had a prescription with a longer-than-recommended duration. We found that patient age, sex, rural-urban status, and type of outpatient clinical setting were associated with antibiotic prescribing for acute sinusitis. Although we observed a statistically significant association between guideline-concordant antibiotic agent selection and certain factors (eg, patient age, sex), such associations had a small magnitude of effect and might be less clinically relevant than the discrepancies identified with prescribing guideline-concordant durations.

Antibiotic therapy for acute sinusitis is often unnecessary [9, 10]. In our study, 17% of encounters did not result in an antibiotic prescription. Although we were unable to assess the clinical criteria used to diagnose acute bacterial sinusitis, this percentage likely reflects the overtreatment of adults with antibiotic therapy. Most cases of acute sinusitis have a viral etiology, and a recent cross-sectional study showed that approximately 50% of encounters for sinusitis do not warrant an antibiotic prescription [9, 11]. In this study, only encounters at an emergency department had such high proportion, with 57% of them not resulting in an antibiotic prescription. A cross-sectional study based on data from national health care surveys in the United States found that presenting to an emergency department for acute sinusitis was not associated with receipt of an antibiotic prescription and, in certain geographic regions, primary care office visits may be more likely to result in an antibiotic prescription [25]. Therefore, it is possible that certain strategies are being implemented in emergency departments to decrease antibiotic prescribing for certain common outpatient conditions, such as sinusitis. Watchful waiting and delayed prescribing are reasonable strategies for the initial management of patients with acute sinusitis with mild symptoms who do not meet the stringent clinical criteria for establishing a bacterial infection [9, 21]. Antibiotic stewardship programs can focus on promoting these strategies and addressing barriers that prescribers might face, such as perceived patient expectations and concern for patient satisfaction. Evidence shows that outpatient antibiotic prescribing can be improved and patients may still be satisfied without an antibiotic if their communication expectations are met [26]. Our study also shows that even when an antibiotic is prescribed, opportunities still exist to optimize guideline-concordant agent selection and duration for acute sinusitis.

Clinical guidelines recommend against the use of macrolides for acute sinusitis [9, 21]. Despite this, we found that azithromycin was the second-most prescribed antibiotic. This finding is consistent with other studies showing frequent prescribing of macrolides for acute sinusitis [8, 11]. Furthermore, we observed that even when guideline-concordant agents are selected, these are predominantly prescribed for longer than recommended, which can lead to excess patient harm. C difficile infection is a well-known antibiotic-associated adverse event, and it has been shown that the risk of this infection increases with antibiotic duration [4, 5]. This risk can be reduced by prescribing guideline-concordant durations, leading to similar outcomes and fewer adverse events as compared with longer durations [27]. Therefore, it is important that antibiotic stewardship programs develop interventions aimed at improving overall prescribing for acute sinusitis. Successful strategies that have increased guideline-concordant prescribing for acute upper respiratory tract infections, such as acute sinusitis, have followed the CDC’s “Core Elements of Outpatient Antibiotic Stewardship” [28]. For example, a before-and-after interrupted time series analysis showed that a multimodal intervention consisting of a targeted education campaign and a prescribing dashboard significantly reduced inappropriate prescribing rates in all outpatient specialties [29]. Another health care system implemented clinical decision support tools to facilitate the gathering of relevant information that would help ensure guideline-concordant diagnoses and provide nudges for guideline-concordant prescribing [30]. When these clinical decision support tools were combined with audit and feedback, the health care system observed increased guideline-concordant antibiotic use [30]. Antibiotic stewardship programs can adopt and tailor such strategies based on additional patient- and prescriber-level factors.

Age appeared to be a patient-level factor associated with antibiotic prescribing for acute sinusitis, especially regarding duration of treatment. We observed that encounters for adults aged 25 to 64 years were more likely to have a prescription with guideline-concordant duration as compared with encounters for younger adults aged 18 to 24 years. When all outpatient encounters for younger adults were evaluated, this patient population had a high proportion of encounters resulting in no antibiotic prescription (21%) or in a guideline-discordant agent (29%). These encounters were excluded from the regression model so that we could evaluate the selection of treatment duration only from encounters that resulted in a guideline-concordant agent. It is possible that our finding might reflect a difference in the clinical management of younger adults with acute sinusitis. Since incidence rates of sinusitis are higher among adults aged 45 to 74 years, there may be differences in the type or specialty of prescribers seeing young adults with sinusitis, which could result in different prescribing practices when compared with other adult patient populations [31].

We observed that encounters among adults residing in rural areas were more likely to result in an antibiotic prescription and were also more likely to have a longer duration as compared with encounters in urban settings. These findings are consistent with other studies showing that rural residence is associated with a higher likelihood of receiving an antibiotic prescription and for that prescription to be inappropriate [32–34]. These differences in prescribing practices for patients could be attributed to various patient- and prescriber-level factors. For example, patients residing in rural areas may have to travel longer distances to see a prescriber and may be more likely to request an antibiotic prescription during their encounter [35, 36]. In addition to potential patient expectations, prescribers may feel pressured to prescribe broader-spectrum antibiotics and longer durations if they are concerned that patients may develop complications from the infection and be unable to access follow-up care [36]. Finally, the number of late-career prescribers practicing in rural areas continues to increase, and some studies suggest that they are more likely to prescribe longer courses of antibiotics [37, 38].

The type of outpatient setting was associated with prescribing practices; as compared with office settings, urgent care encounters were less likely to have a guideline-concordant duration. A cross-sectional study assessing prescribing practices across an integrated health care system also found that urgent care encounters for acute sinusitis were significantly less likely to result in a prescription with a guideline-concordant duration [39]. Urgent care prescribers might be more inclined to prescribe an antibiotic and a longer course of therapy potentially due to less familiarity with treatment recommendations and guidelines, a lack of a relationship with patients, or concerns that patients may not seek additional follow-up if their condition worsens or will not use urgent care in the future because their expectations were not met [40, 41]. Antibiotic stewardship programs that have implemented interventions aimed at addressing patient- and prescriber-level factors influencing prescribing in the urgent care setting, such as initiatives addressing patient expectations, have successfully improved antibiotic prescribing [42].

This study has several potential limitations. First, using ICD-10 diagnosis codes to identify the study population may result in misclassification. Second, administrative claims cannot ascertain the severity of infection and other factors (eg, signs or symptoms of infection) that could influence antibiotic prescribing and the assessment of whether the antibiotic prescriptions were clinically indicated. Third, the Merative MarketScan Commercial Database does not capture dosing information, and we were unable to include antibiotic agent dosing in the definition of guideline-concordant prescribing. Fourth, we did not exclude encounters for patients with a previous sinusitis diagnosis (5% of total encounters had a sinusitis diagnosis in the preceding 30 days). Prescribers may choose non–first-line antibiotics with a broader or different activity spectrum than first-line agents for patients with recurrent acute sinusitis. However, given the categorization of second-line agents (eg, fluoroquinolones) more commonly prescribed for recurrent cases as guideline concordant, the effect of including these encounters may be minimized. Fifth, we did not include prescriber type/specialty in our regression analysis because of potential collinearity with type of outpatient setting. Sixth, additional patient characteristics related to health inequities in health care access and antibiotic prescribing, such as race and ethnicity, income, or education level, were not assessed since these variables were not available in these data [43]. Last, this study included only commercially insured adults aged 18 to 64 years and thus may not be generalizable to other age groups or populations. Despite these limitations, this study characterized patient- and prescriber-level factors associated with appropriate antibiotic prescribing for acute sinusitis in a large cohort of commercially insured adults from all 50 US states and the District of Columbia.

In conclusion, this study demonstrates that specific patient- and prescriber-level factors are associated with the guideline-concordant management of acute sinusitis among commercially insured adults. Specifically, our results indicate that rural areas and urgent care settings had lower guideline-concordant antibiotic prescribing for acute sinusitis. Antibiotic stewardship activities should be tailored to the patient population, prescriber type/specialty, and type of outpatient setting where they are being implemented. Opportunities exist to optimize antibiotic prescribing, especially to reduce unnecessary prescribing and duration of therapy for acute sinusitis.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. A. A. V. D., A. M. B., L.A.H., and S. K. conceived and designed the study. D. J. B., and J. M. S. performed the statistical analyses. A. A. V. D. drafted the initial manuscript. All authors contributed to the interpretation of the results and revised the manuscript for substantial content. All authors read and approved the final manuscript.

Disclaimer. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Patient consent. This study does not include factors necessitating patient consent.

Financial support. No funding external to the Centers for Disease Control and Prevention was provided for this study.

References

1

Centers for Disease Control and Prevention
.
Antibiotic resistance threats in the United States, 2019. Washington, DC: US Department of Health and Human Services
,
2019
. Available at: http://dx.doi.org/10.15620/cdc:82532

2

Costelloe
 
C
,
Metcalfe
 
C
,
Lovering
 
A
,
Mant
 
D
,
Hay
 
AD
.
Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis
.
BMJ
 
2010
;
340
:
c2096
.

3

Shehab
 
N
,
Patel
 
PR
,
Srinivasan
 
A
,
Budnitz
 
DS
.
Emergency department visits for antibiotic-associated adverse events
.
Clin Infect Dis
 
2008
;
47
:
735
43
.

4

Brown
 
KA
,
Langford
 
B
,
Schwartz
 
KL
,
Diong
 
C
,
Garber
 
G
,
Daneman
 
N
.
Antibiotic prescribing choices and their comparative C difficile infection risks: a longitudinal case-cohort study
.
Clin Infect Dis
 
2021
;
72
:
836
44
.

5

Di Bella
 
S
,
Sanson
 
G
,
Monticelli
 
J
, et al.  
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options
.
Clin Microbiol Rev
 
2024
;
37
:
e0013523

6

Fleming-Dutra
 
KE
,
Hersh
 
AL
,
Shapiro
 
DJ
, et al.  
Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011
.
JAMA
 
2016
;
315
:
1864
73
.

7

King
 
LM
,
Tsay
 
SV
,
Hicks
 
LA
,
Bizune
 
D
,
Hersh
 
AL
,
Fleming-Dutra
 
K
.
Changes in outpatient antibiotic prescribing for acute respiratory illnesses, 2011 to 2018
.
Antimicrob Steward Healthc Epidemiol
 
2021
;
1
:
1
8
.

8

King
 
LM
,
Sanchez
 
GV
,
Bartoces
 
M
,
Hicks
 
LA
,
Fleming-Dutra
 
KE
.
Antibiotic therapy duration in US adults with sinusitis
.
JAMA Intern Med
 
2018
;
178
:
992
4
.

9

Chow
 
AW
,
Benninger
 
MS
,
Brook
 
I
, et al.  
IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults
.
Clin Infect Dis
 
2012
;
54
:
e72
112
.

10

Gwaltney
 
JM
 Jr,
Wiesinger
 
BA
,
Patrie
 
JT.
 
Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history
.
Clin Infect Dis
 
2004
;
38
:
227
33
.

11

Truitt
 
KN
,
Brown
 
T
,
Lee
 
JY
,
Linder
 
JA
.
Appropriateness of antibiotic prescribing for acute sinusitis in primary care: a cross-sectional study
.
Clin Infect Dis
 
2021
;
72
:
311
4
.

12

Suda
 
KJ
,
Roberts
 
RM
,
Hunkler
 
RJ
,
Taylor
 
TH
.
Antibiotic prescriptions in the community by type of provider in the United States, 2005–2010
.
J Am Pharm Assoc
 
2016
;
56
:
621
6.e1
.

13

Hicks
 
LA
,
Bartoces
 
MG
,
Roberts
 
RM
, et al.  
US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011
.
Clin Infect Dis
 
2015
;
60
:
1308
16
.

14

Schmidt
 
ML
,
Spencer
 
MD
,
Davidson
 
LE
.
Patient, provider, and practice characteristics associated with inappropriate antimicrobial prescribing in ambulatory practices
.
Infect Control Hosp Epidemiol
 
2018
;
39
:
307
15
.

15

Barlam
 
TF
,
Soria-Saucedo
 
R
,
Cabral
 
HJ
,
Kazis
 
LE
.
Unnecessary antibiotics for acute respiratory tract infections: association with care setting and patient demographics
.
Open Forum Infect Dis
 
2016
;
3
:
ofw045
.

16

King
 
LM
,
Hicks
 
LA
,
Fleming-Dutra
 
KE
.
Further considerations regarding duration of antibiotic therapy for sinusitis—reply
.
JAMA Intern Med
 
2018
;
178
:
1138
9
.

17

Smith
 
SS
,
Kern
 
RC
,
Chandra
 
RK
,
Tan
 
BK
,
Evans
 
CT
.
Variations in antibiotic prescribing of acute rhinosinusitis in United States ambulatory settings
.
Otolaryngol Head Neck Surg
 
2013
;
148
:
852
9
.

18

Palms
 
DL
,
Hicks
 
LA
,
Bartoces
 
M
, et al.  
First-line antibiotic selection in outpatient settings
.
Antimicrob Agents Chemother
 
2019
;
63
:
e01060-19
.

19

Butler
 
AM
,
Nickel
 
KB
,
Overman
 
RA
,
Brookhart
 
MA
. IBM MarketScan research databases. In:
Sturkenboom
 
M
,
Schink
 
T
, eds.
Databases for pharmacoepidemiological research springer series on epidemiology and public health
. New York:
Springer
,
2021
:
243
51
.

20

IBM
.
White paper: IBM MarketScan research databases for life sciences researchers
.
2021
. Accessed 18 August 2022. Available at: https://www.ibm.com/downloads/cas/OWZWJ0QO.

21

Rosenfeld
 
RM
,
Piccirillo
 
JF
,
Chandrasekhar
 
SS
, et al.  
Clinical practice guideline (update): adult sinusitis executive summary
.
Otolaryngol Head Neck Surg
 
2015
;
152
:
598
609
.

22

Rovelsky
 
SA
,
Remington
 
RE
,
Nevers
 
M
, et al.  
Comparative effectiveness of amoxicillin versus amoxicillin-clavulanate among adults with acute sinusitis in emergency department and urgent care settings
.
J Am Coll Emerg Physicians Open
 
2021
;
2
:
e12465
.

23

Office of Management and Budget
.
Standards for delineating metropolitan and micropolitan statistical areas
.
Fed Regist
 
2010
;
75
:
37245
52
.

24

von Elm
 
E
,
Altman
 
DG
,
Egger
 
M
, et al.  
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
.
PLoS Med
 
2007
;
4
:
e296
.

25

Bergmark
 
RW
,
Sedaghat
 
AR
.
Antibiotic prescription for acute rhinosinusitis: emergency departments versus primary care providers
.
Laryngoscope
 
2016
;
126
:
2439
44
.

26

King
 
LM
,
Fleming-Dutra
 
KE
,
Hicks
 
LA
.
Advances in optimizing the prescription of antibiotics in outpatient settings
.
BMJ
 
2018
;
363
:
k3047
.

27

Falagas
 
ME
,
Karageorgopoulos
 
DE
,
Grammatikos
 
AP
,
Matthaiou
 
DK
.
Effectiveness and safety of short vs long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials
.
Br J Clin Pharmacol
 
2009
;
67
:
161
71
.

28

Sanchez
 
GV
,
Fleming-Dutra
 
KE
,
Roberts
 
RM
,
Hicks
 
LA
.
Core elements of outpatient antibiotic stewardship
.
MMWR Recomm Rep
 
2016
;
65
:
1
12
.

29

Davidson
 
LE
,
Gentry
 
EM
,
Priem
 
JS
,
Kowalkowski
 
M
,
Spencer
 
MD
.
A multimodal intervention to decrease inappropriate outpatient antibiotic prescribing for upper respiratory tract infections in a large integrated healthcare system
.
Infect Control Hosp Epidemiol
 
2023
;
44
:
392
9
.

30

Wasylyshyn
 
AI
,
Kaye
 
KS
,
Chen
 
J
, et al.  
Improving antibiotic use for sinusitis and upper respiratory tract infections: a virtual-visit antibiotic stewardship initiative
.
Infect Control Hosp Epidemiol
 
2022
;
43
:
1890
3
.

31

Villarroel
 
MA
,
Blackwell
 
DL
,
Jen
 
A
.
Tables of summary health statistics for US adults: 2018 national health interview survey
. Hyattsville, MD:
National Center for Health Statistics
,
2019
.

32

Brown
 
DW
,
Taylor
 
R
,
Rogers
 
A
,
Weiser
 
R
,
Kelley
 
M
.
Antibiotic prescriptions associated with outpatient visits for acute upper respiratory tract infections among adult Medicaid recipients in North Carolina
.
N C Med J
 
2003
;
64
:
148
56
.

33

Evans
 
CT
,
Fitzpatrick
 
MA
,
Poggensee
 
L
, et al.  
Outpatient prescribing of antibiotics and opioids by veterans health administration providers, 2015–2017
.
Am J Prev Med
 
2021
;
61
:
e235
44
.

34

Winders
 
HR
,
Royer
 
J
,
Younas
 
M
, et al.  
Temporal trends in ambulatory antibiotic prescription rates in South Carolina: impact of age, gender, and resident location
.
Infect Control Hosp Epidemiol
 
2020
;
41
:
879
82
.

35

Duane
 
S
,
Domegan
 
C
,
Callan
 
A
, et al.  
Using qualitative insights to change practice: exploring the culture of antibiotic prescribing and consumption for urinary tract infections
.
BMJ Open
 
2016
;
6
:
e008894
.

36

Appaneal
 
HJ
,
Caffrey
 
AR
,
Lopes
 
V
,
Dosa
 
D
,
LaPlante
 
KL
.
Antibiotic prescribing in outpatient settings: rural patients are more likely to receive fluoroquinolones and longer antibiotic courses
.
Antibiotics (Basel)
 
2023
;
12
:
224
.

37

Skinner
 
L
,
Staiger
 
DO
,
Auerbach
 
DI
,
Buerhaus
 
PI
.
Implications of an aging rural physician workforce
.
N Engl J Med
 
2019
;
381
:
299
301
.

38

Fernandez-Lazaro
 
CI
,
Brown
 
KA
,
Langford
 
BJ
,
Daneman
 
N
,
Garber
 
G
,
Schwartz
 
KL
.
Late-career physicians prescribe longer courses of antibiotics
.
Clin Infect Dis
 
2019
;
69
:
1467
75
.

39

Vazquez Deida
 
AA
,
Shihadeh
 
KC
,
Aragon
 
D
,
Knepper
 
BC
,
Jenkins
 
TC
.
Factors associated with longer than recommended durations of antibiotic therapy for uncomplicated ambulatory infections in an integrated healthcare system
.
Open Forum Infect Dis
 
2021
;
8
:
ofab324
.

40

Incze
 
MA
,
Redberg
 
RF
,
Katz
 
MH
.
Overprescription in urgent care clinics—the fast and the spurious
.
JAMA Intern Med
 
2018
;
178
:
1269
70
.

41

Cziner
 
MJ
,
Park
 
DE
,
Hamdy
 
RF
,
Rogers
 
LA
,
Turner
 
MM
,
Liu
 
CM
.
Effects of patient beliefs regarding the need for antibiotics and prescribing outcomes on patient satisfaction in urgent-care settings
.
Antimicrob Steward Healthc Epidemiol
 
2023
;
3
:
e83
.

42

Stenehjem
 
E
,
Wallin
 
A
,
Willis
 
P
, et al.  
Implementation of an antibiotic stewardship initiative in a large urgent care network
.
JAMA Netw Open
 
2023
;
6
:
e2313011
.

43

Kim
 
C
,
Kabbani
 
S
,
Dube
 
WC
, et al.  
Health equity and antibiotic prescribing in the United States: a systematic scoping review
.
Open Forum Infect Dis
 
2023
;
10
:
ofad440
.

Author notes

Potential conflicts of interest. A. M. B. has received investigator-initiated research funding from Merck on topics unrelated to this work. All other authors report no potential conflicts.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.